Bristol-Myers Squibb Co. [BMY] stock prices are up 1.33% to $53.25 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BMY shares have gain 2.64% over the last week, with a monthly amount glided 5.42%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes. In a post published today on Yahoo Finance, Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom.
From an analyst’s perspective:
Bristol-Myers Squibb Co. [NYSE: BMY] stock has seen the most recent analyst activity on March 11, 2024, when Societe Generale downgraded its rating to a Hold. Previously, Redburn Atlantic downgraded its rating to Neutral on February 06, 2024, and dropped its price target to $54. On January 03, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $60 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral and decreased its price target to $55 on November 15, 2023. Deutsche Bank initiated its recommendation with a Hold and recommended $55 as its price target on November 09, 2023. Daiwa Securities downgraded its rating to Neutral for this stock on November 02, 2023, and downed its price target to $54. In a note dated October 27, 2023, HSBC Securities upgraded an Hold rating on this stock and revised its target price from $55 to $53.
The stock price of Bristol-Myers Squibb Co. [BMY] has been fluctuating between $47.58 and $71.07 over the past year. Currently, Wall Street analysts expect the stock to reach $70.55 within the next 12 months. Bristol-Myers Squibb Co. [NYSE: BMY] shares were valued at $53.25 at the most recent close of the market. An investor can expect a potential return of 32.49% based on the average BMY price forecast.
Analyzing the BMY fundamentals
The Bristol-Myers Squibb Co. [NYSE:BMY] reported sales of 45.01B for trailing twelve months, representing a surge of 0.62%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.26 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 52.84 points at the first support level, and at 52.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.68, and for the 2nd resistance point, it is at 54.10.
Bristol-Myers Squibb Co. [BMY] reported earnings per share of $1.7 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.53/share, meaning a difference of $0.17 and a surprise factor of 11.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.82 per share as compared to estimates of $1.61 per share, a difference of $0.21 representing a surprise of 13.00%.
Ratios To Look Out For
It’s worth pointing out that Bristol-Myers Squibb Co. [NYSE:BMY]’s Current Ratio is 1.43. On the other hand, the Quick Ratio is 1.31, and the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 2.39, the price to book ratio is 3.66 and price to earnings (TTM) ratio is 13.80.
Transactions by insiders
Recent insider trading involved BOERNER CHRISTOPHER S., Chief Executive Officer, that happened on Dec 05 ’23 when 2000.0 shares were purchased. Chief Executive Officer, BOERNER CHRISTOPHER S. completed a deal on Nov 28 ’23 to buy 3071.0 shares. Meanwhile, Director Samuels Theodore R. II bought 8500.0 shares on Nov 20 ’23.
